- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05075876
Bioequivalence Study in Healthy Chinese Subjects Comparing SP-01 (Granisetron Patch) Manufactured at Two Different Sites
February 7, 2022 updated by: Solasia Pharma K.K.
An Open-Label, Randomized, Single-Center, Two-period, Two-sequence Cross-over Study to Assess the Bioequivalence of a Single 6-day Application of SP-01 (Granisetron Patch) Manufactured at Two Different Sites in Healthy Chinese Subjects
This study is an open-label, single-center, two-period, two-sequence crossover study to assess the bioequivalence of SP-01 (Sancuso®: Granisetron Patch) manufactured at two different sites.
Either the test product, namely SP-01-K, or reference product, namely SP-01-A, will be applied to the subject once in each period.
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
66
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Hong Kong, Hong Kong
- Phase 1 Clinical Trials Centre, The University of Hong Kong
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Han Chinese male or female subject, with all of his/her biological parents and grandparents are of Han Chinese ethnicity (who do not belong to any Chinese minorities)
- Subject aged between 18 and 55 years, inclusive, at the time of signing the informed consent form
- Body weight ≥ 45 kg and body mass index (BMI) of 18 to 25 kg/m2, inclusive.
- Generally in good health with no clinically significant abnormality. Clinically insignificant abnormalities may be acceptable at the discretion of the investigator.
Female subject.
- Non-childbearing potential
- For female subject of childbearing potential who used (and/have their partner used) two acceptable contraceptive methods for at least 4 weeks prior to the first dose of study drug, and agree to use two contraceptive methods during the entire study period and within 3 weeks after the patch removal in Period 2. If abstinence is an alternative lifestyle, subject who is practicing abstinence and agree to practice abstinence throughout the above-mentioned periods may be included into the study.
Male subject.
- If male subject has a female partner with childbearing potential, he has used (or has his partner used) two acceptable contraceptive methods for at least 4 weeks prior to the first dose of study drug, and must agree to use (or has his partner used) two contraceptive methods during the entire study period and within 3 weeks after the patch removal in Period 2. If abstinence is an alternative lifestyle, subject who is practicing abstinence and agree to practice abstinence throughout the above-mentioned periods may be included into the study.
- Ability to understand the nature, scope and possible consequences of participation in the study
- Willing to comply with the study procedures and restrictions
- Willing to give written informed consent voluntarily
Exclusion Criteria:
- Known significant allergic conditions to any medications in general, or to transdermal therapeutic systems (e.g. Elastoplast®) or medical adhesive tapes/dressings in particular.
- Concurrent clinically significant conditions or known history of clinically significant conditions including but not limited to hepatobiliary & pancreatic, renal, urinary, respiratory, gastrointestinal, endocrine, cardiovascular, neurological, immunological, haematological, musculoskeletal, dermatological and/or psychiatric disorders.
- Subject has estimated creatinine clearance ≤ 80 mL/min calculated by Cockcroft Gault formula prior to the first dose of study drug.
- Subject has abnormal Alanine Aminotransferase (ALT) and/or Aspartate Aminotransferase (AST) values prior to the first dose of study drug and the abnormality, as determined by investigators, makes the subject not suitable for participation in the study.
- Subject has history of uncontrollable migraine or headaches.
- Subject has any skin conditions (e.g. tattoos, wounds, oily skin) or diseases (e.g. dermatological disorder) that may hinder clinical assessments on the upper lateral arm where the study drug is applied.
- Any conditions or illnesses that in the opinion of the Investigator may jeopardize subjects or interfere with the interpretation of study results.
- Has used any prescribed or over-the-counter medication, vitamins, herbal supplements, vaccines, and/or hormonal contraceptive pill/patch/injection within 14-day period (use of acetaminophen/paracetamol as sole active ingredient within 7 days) prior to the first dosing of the study drug (Day 1). Exceptions include topical medications or eye drops with no systemic action.
- Participation in any clinical studies which involve the use of investigational medicinal product(s) within 3 months prior to the first dose of study drug.
- Blood loss or donation of more than 450 ml within 3 months prior to the first dose of study drug.
- Female subject who is lactating or has positive pregnancy test result prior to the first dose of study drug.
- Has not constantly resided in Hong Kong or with recent significant change in lifestyle and habits, including diet and exercise.
- Engaged in strenuous exercise within 14 days prior to the first dose of study drug or unwilling to stop strenuous exercise throughout the entire duration of the study.
- Refuse to refrain from swimming, prolonged soaking in water (e.g. bathing), sauna or activities that cause excessive sweating when wearing a study patch.
- Refuse to refrain from activities such as sunbathing or tanning using tanning bed/sunlamps that expose the application site to direct sunlight when wearing a patch and within 10 days after the patch removal.
- Refuse to avoid scrubbing and shaving the patch application site from 48 hours prior to patch application and when wearing a patch.
- Refuse to avoid application of creams, lotions or oils to the patch application site from 48 hours prior to patch application and when wearing a patch.
- Refuse to abstain from consuming grapefruit or grapefruit-containing beverages from 48 hours prior to the first patch application until the last PK blood sampling on Day 11 in each period
- Regular consumption of large quantities of xanthine-containing beverages such as coffee, tea, chocolate, cola or other caffeinated beverages, defined as more than 6 cups per day within 3 months prior to signing informed consent.
- Refuse to restrict the consumption of xanthine-containing beverages to a maximum of 2 cups per day during screening and Day 12 to Day 25 of period 1, and refuse to abstain from consuming xanthine-containing beverages from 48 hours prior to patch application until the last PK blood sampling on Day 11 in each period.
- Regular consumption of alcoholic beverages that exceeds 14 units per week (1 unit = 360 ml of beer; 150 ml of wine; 45 ml of distilled spirits) within 3 months prior to signing informed consent.
- Refuse to restrict the consumption of alcoholic beverages to a maximum of 1 unit per day during screening and Day 12 to Day 25 of period 1, and refuse to abstain from alcoholic beverages from 48 hours prior to patch application until the last PK blood sampling on Day 11 in each period.
- Regular tobacco smoking or using nicotine containing product of more than 3 cigarettes per day within 3 months prior to signing informed consent.
- Refuse to abstain from tobacco smoking or using nicotine containing product from screening until Day 11 of Period 2.
- History of substance (alcohol or illicit drugs) abuse/addiction in the past 5 years, or used illicit drugs 3 months prior to signing informed consent, or positive urine drug test and blood alcohol test prior to the first dose of study drug.
- Subject has an immediate family member (e.g. spouse, parent/legal guardian, sibling or child) who is the study site or sponsor staff and directly involved with this study.
- Any other concerns that the Investigator considers the subject not suitable for participation in the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Group 1 (SP-01-K)
Application of SP-01 manufactured by Site K (SP-01-K) for 6 days followed by washout period for 21 days followed by application of SP-01 manufactured by Site A (SP-01-A) for 6 days
|
Single application for 6 days
Single application for 6 days
|
ACTIVE_COMPARATOR: Group 2 (SP-01-A)
Application of SP-01 manufactured by Site A (SP-01-A) for 6 days followed by washout period for 21 days followed by application of SP-01 manufactured by Site K (SP-01-K) for 6 days
|
Single application for 6 days
Single application for 6 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum observed drug concentration (Cmax)
Time Frame: 11 days
|
Maximum observed drug concentration in plasma
|
11 days
|
Area under the concentration-time curve (AUC) 0-t
Time Frame: 11 days
|
Area under the plasma concentration-time curve from time zero to time t, where t is the last time point with non-zero concentration
|
11 days
|
AUC0-∞
Time Frame: 11 days
|
Area under the plasma concentration-time curve from time zero to time infinity
|
11 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to reach Cmax (Tmax)
Time Frame: 11 days
|
Time to reach the maximum observed drug concentration in plasma
|
11 days
|
Terminal elimination rate constant (λZ)
Time Frame: 11 days
|
Apparent terminal phase rate constant, where λZ is the magnitude of the slope of the linear regression of the log concentration versus time profile during the terminal phase
|
11 days
|
Elimination half-life (t1/2)
Time Frame: 11 days
|
The time required for the observed drug concentration in plasma to reach half of its original value
|
11 days
|
Adverse event
Time Frame: 38 days
|
Incidence of adverse events
|
38 days
|
Adhesion
Time Frame: 7 days
|
Mean adhesion score, which is the average of adhesion scores of a subject in a period
|
7 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Bernard Man Yung Cheung, Phase 1 Clinical Trials Centre, The University of Hong Kong
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
October 13, 2021
Primary Completion (ACTUAL)
December 3, 2021
Study Completion (ACTUAL)
December 3, 2021
Study Registration Dates
First Submitted
September 21, 2021
First Submitted That Met QC Criteria
October 8, 2021
First Posted (ACTUAL)
October 13, 2021
Study Record Updates
Last Update Posted (ACTUAL)
February 9, 2022
Last Update Submitted That Met QC Criteria
February 7, 2022
Last Verified
February 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SP-0105
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteers
-
AstraZenecaCompletedHealthy Elderly Volunteers | Healthy Young VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
University Hospital, Clermont-FerrandUnite de Nutrition Humaine UMR 1019- INRAE; Unite MetaGenoPolis INRAE; France...CompletedHealthy Volunteers | Frail VolunteersFrance
-
Galera Therapeutics, Inc.CelerionCompletedHealthy | Healthy VolunteersUnited States
-
Newcastle UniversityCompletedGI Glycaemic Index Healthy Volunteers | GL Glycaemic Load Healthy VolunteersUnited Kingdom
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
PMV Pharmaceuticals, IncRecruitingHealthy VolunteersUnited States
Clinical Trials on SP-01 manufactured by Site K (SP-01-K, Transdermal patch contained granisetron)
-
Solasia Pharma K.K.Proswell Medical CorporationCompletedChemotherapy-induced Nausea and VomitingChina